NASDAQ:CALA - Calithera Biosciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $3.67
  • Forecasted Upside: 56.03 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.35
▼ -0.05 (-2.08%)

This chart shows the closing price for CALA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Calithera Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CALA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CALA

Analyst Price Target is $3.67
▲ +56.03% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Calithera Biosciences in the last 3 months. The average price target is $3.67, with a high forecast of $5.00 and a low forecast of $2.00. The average price target represents a 56.03% upside from the last price of $2.35.

This chart shows the closing price for CALA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Calithera Biosciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/6/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/5/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/3/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/1/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/1/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/30/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/28/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/9/2021HC WainwrightReiterated RatingBuy$4.00Low
5/10/2021HC WainwrightReiterated RatingBuy$4.00High
1/5/2021Smith Barney CitigroupLower Price Target$10.00 ➝ $5.00N/A
1/5/2021HC WainwrightLower Price TargetBuy$9.50 ➝ $4.00N/A
1/5/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$7.00 ➝ $2.00N/A
8/11/2020SVB LeerinkLower Price TargetOutperform$9.00 ➝ $7.00High
6/2/2020William BlairReiterated RatingBuyMedium
5/11/2020CitigroupBoost Price TargetBuy$7.00 ➝ $10.00High
5/8/2020HC WainwrightReiterated RatingBuy$7.00 ➝ $9.50High
3/27/2020CitigroupLower Price TargetBuy$8.00 ➝ $7.00High
3/27/2020Jefferies Financial GroupInitiated CoverageBuy$6.00High
3/11/2020SVB LeerinkReiterated RatingOutperformHigh
11/27/2019HC WainwrightInitiated CoverageBuy$7.00High
11/19/2019HC WainwrightInitiated CoverageBuy$7.00High
8/9/2019CitigroupSet Price TargetHold$8.00Medium
6/21/2019William BlairReiterated RatingBuyLow
5/30/2019CitigroupReiterated RatingBuy$10.00Medium
4/6/2018SVB LeerinkReiterated RatingOutperformMedium
2/16/2018CitigroupUpgradeNeutral ➝ Buy$6.95 ➝ $14.00High
10/5/2017William BlairInitiated CoverageOutperform ➝ OutperformN/A
6/12/2017HC WainwrightReiterated RatingBuy$14.00 ➝ $19.00Low
6/6/2017Wells Fargo & CompanyReiterated RatingOutperform$15.00 ➝ $20.00High
4/3/2017SVB LeerinkReiterated RatingOutperform ➝ Outperform$16.00Medium
3/28/2017JMP SecuritiesReiterated RatingOutperform$12.00 ➝ $12.00Medium
3/28/2017HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $14.00Medium
2/2/2017HC WainwrightSet Price TargetBuy$10.00N/A
1/30/2017JMP SecuritiesReiterated RatingOutperform$12.00N/A
1/24/2017CitigroupUpgradeSell ➝ Neutral$5.00N/A
1/5/2017HC WainwrightInitiated CoverageBuy$9.00N/A
12/1/2016JMP SecuritiesReiterated RatingBuyN/A
11/10/2016JMP SecuritiesReiterated RatingBuyN/A
10/25/2016CitigroupInitiated CoverageSellN/A
(Data available from 9/28/2016 forward)

News Sentiment Rating

-0.34 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/2/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/30/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/29/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
9/28/2021

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Calithera Biosciences logo
Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor. The company was founded by James A. Wells and Susan M. Molineaux on March 9, 2010 and is headquartered in South San Francisco, CA.
Read More

Today's Range

Now: $2.35
Low: $2.32
High: $2.37

50 Day Range

MA: $2.20
Low: $1.90
High: $2.45

52 Week Range

Now: $2.35
Low: $1.78
High: $6.18

Volume

11,188 shs

Average Volume

1,106,411 shs

Market Capitalization

$174.17 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.69

Frequently Asked Questions

What sell-side analysts currently cover shares of Calithera Biosciences?

The following sell-side analysts have issued reports on Calithera Biosciences in the last year: HC Wainwright, Smith Barney Citigroup, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for CALA.

What is the current price target for Calithera Biosciences?

3 Wall Street analysts have set twelve-month price targets for Calithera Biosciences in the last year. Their average twelve-month price target is $3.67, suggesting a possible upside of 52.8%. Smith Barney Citigroup has the highest price target set, predicting CALA will reach $5.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $2.00 for Calithera Biosciences in the next year.
View the latest price targets for CALA.

What is the current consensus analyst rating for Calithera Biosciences?

Calithera Biosciences currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CALA will outperform the market and that investors should add to their positions of Calithera Biosciences.
View the latest ratings for CALA.

How do I contact Calithera Biosciences' investor relations team?

Calithera Biosciences' physical mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company's listed phone number is (650) 870-1000 and its investor relations email address is [email protected] The official website for Calithera Biosciences is www.calithera.com.